These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 23249646)
1. Interscanner comparison of dynamic contrast-enhanced MRI in prostate cancer: 1.5 versus 3 T MRI. Sertdemir M; Schoenberg SO; Sourbron S; Hausmann D; Heinzelbecker J; Michaely HJ; Dinter DJ; Weidner AM Invest Radiol; 2013 Feb; 48(2):92-7. PubMed ID: 23249646 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330 [TBL] [Abstract][Full Text] [Related]
3. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Franiel T; Lüdemann L; Rudolph B; Rehbein H; Stephan C; Taupitz M; Beyersdorff D Radiology; 2009 Jul; 252(1):101-8. PubMed ID: 19561252 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer]. Franiel T; Lüdemann L; Taupitz M; Rost J; Asbach P; Beyersdorff D Rofo; 2009 Jun; 181(6):536-42. PubMed ID: 19353483 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of DTI in prostate cancer. Gürses B; Tasdelen N; Yencilek F; Kılıckesmez NO; Alp T; Fırat Z; Albayrak MS; Uluğ AM; Gürmen AN Eur J Radiol; 2011 Aug; 79(2):172-6. PubMed ID: 20138721 [TBL] [Abstract][Full Text] [Related]
6. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Franiel T; Lüdemann L; Taupitz M; Böhmer D; Beyersdorff D Radiother Oncol; 2009 Nov; 93(2):241-5. PubMed ID: 19748143 [TBL] [Abstract][Full Text] [Related]
7. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Nagel KN; Schouten MG; Hambrock T; Litjens GJ; Hoeks CM; ten Haken B; Barentsz JO; Fütterer JJ Radiology; 2013 Apr; 267(1):164-72. PubMed ID: 23329653 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184 [TBL] [Abstract][Full Text] [Related]
9. Value of multiparametric prostate MRI of the peripheral zone. Weidner AM; Michaely HJ; Lemke A; Breitinger L; Wenz F; Marx A; Schoenberg SO; Dinter DJ Z Med Phys; 2011 Sep; 21(3):198-205. PubMed ID: 21247742 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259 [TBL] [Abstract][Full Text] [Related]
11. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768 [TBL] [Abstract][Full Text] [Related]
16. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187 [TBL] [Abstract][Full Text] [Related]
17. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. Beyersdorff D; Taymoorian K; Knösel T; Schnorr D; Felix R; Hamm B; Bruhn H AJR Am J Roentgenol; 2005 Nov; 185(5):1214-20. PubMed ID: 16247137 [TBL] [Abstract][Full Text] [Related]
18. Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. Franiel T; Lüdemann L; Rudolph B; Lutterbeck E; Hamm B; Beyersdorff D AJR Am J Roentgenol; 2010 Mar; 194(3):675-81. PubMed ID: 20173144 [TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082 [TBL] [Abstract][Full Text] [Related]
20. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. Park BK; Kim B; Kim CK; Lee HM; Kwon GY J Comput Assist Tomogr; 2007; 31(4):534-8. PubMed ID: 17882027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]